04:15 PM EDT, 05/01/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target to $528 from $515, 39.4x our 2026 EPS view, a discount to IDXX's five-year historical forward P/E average. We lower our 2025 view to $12.15 from $12.22 and keep our 2026 EPS at $13.41. IDXX delivered a solid start to 2025, with Q1 revenue rising to $998M (+4% Y/Y), broadly in line with expectations. The company's core Companion Animal Group (CAG) business continued to drive performance, with CAG Diagnostics recurring revenue growing 4.5% organically, primarily fueled by strong IDEXX VetLab consumables sales (up 10% organically). In our view, IDXX's strategic focus on innovation and expanding its premium instrument installed base is yielding results, evidenced by the 9% growth in premium instrument placements. We think the successful launch of over 300 IDEXX ( IDXX ) inVue Dx analyzers in Q1 further underscores IDXX's ability to introduce and scale new technologies. Looking ahead, IDXX increased its 2025 revenue guidance, pointing to a robust 5% to 8% Y/Y growth, which we find encouraging.